Topical reviewMedical Management of Pituitary-Dependent Hyperadrenocorticism: Mitotane versus Trilostane (cas 13647-35-3)

Add time:09/10/2019    Source:sciencedirect.com

Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD, Bristol-Myers Squibb, New York) has been the most commonly used treatment for medical management. Its use is complicated and comes with many potential side effects, making many practitioners wary of its use. Recently, trilostane has been proven to be an effective treatment of pituitary-dependent hyperadrenocorticism and is approved for use in other countries. Treatment with trilostane is somewhat simpler and the incidence of side effects seems to be less when compared with mitotane therapy. Either treatment can be a safe and effective method of treatment for pituitary-dependent hyperadrenocorticism when the practitioner and client are well educated regarding their use and an appropriate monitoring protocol is used.

We also recommend Trading Suppliers and Manufacturers of Trilostane (cas 13647-35-3). Pls Click Website Link as below: cas 13647-35-3 suppliers

Prev:Short CommunicationExpression of 11β-hydroxysteroid dehydrogenase isoforms in canine adrenal glands treated with Trilostane (cas 13647-35-3)
Next:The antidepressant-like effects of the 3β-hydroxysteroid dehydrogenase inhibitor Trilostane (cas 13647-35-3) in mice is related to changes in neuroactive steroid and monoamine levels)